- Company
- Lilly prepares to introduce Olumiant for hair loss in Korea
- by Eo, Yun-Ho Oct 7, 2022 06:04am
- JAK inhibitors may soon be prescribed to treat hair loss in Korea as well. According to industry sources, Lilly Korea is preparing to apply and expand the indication for its JAK inhibitor Olumiant (baricitinib) to severe alopecia areata to the Ministry of Food and Drug Safety. After the drug was approved in June for the indication by the
- Company
- GC Pharma sells GSK's new shingles vaccine Shingrix together
- by Kim, Jin-Gu Oct 7, 2022 06:03am
- GC Pharma and GSK will jointly sell the shingles vaccine Shingrix. The two companies are expected to sell a new shingles vaccine as early as the end of this year. According to the pharmaceutical industry on the 6th, GC Pharma and GSK recently signed a co-promotion contract for Shingrix and started product training for salespeople before it
- Company
- Daewoong Pharmaceutical launches botulinum drug in the UK
- by Chon, Seung-Hyun Oct 6, 2022 06:05am
- The botulinum toxin drug developed by Daewoong Pharmaceutical has been released in earnest in the European market. Daewoong Pharmaceutical announced on the 5th that Nabota, a botulinum toxin drug, was officially released in the UK under the product name Nuceiva. It started selling in the UK last month through Daewoong Pharmaceutical's oversea
- Company
- ILSUNG signs 3rd generation CCB HTN tx co-promotion
- by Lee, Seok-Jun Oct 6, 2022 06:05am
- ILSUNG, Intro Bio Pharma, and Pharmavision, have signed a partnership for Azelnidipine copromotion. According to ILSUNG on the 4th, Intro Bio Pharma received the first approval in Korea for Azelnidipine-based medicine in September 2021. Azelnidipine is a third-generation CCB hypertension treatment (Calblock) developed by Daiichi Sankyo Kore
- Company
- Koselugo is keen to discuss the registration of benefits
- by Eo, Yun-Ho Oct 5, 2022 06:11am
- Attention is focusing on whether Koselugo, a drug-free treatment for neurofibroma, will succeed in registering insurance benefits. According to related industries, AstraZeneca's new neurofibromatosis drug Koselugo is under final coordination at the Drug Benefit Standards Subcommittee. AstraZeneca quickly supplemented the data in May and resum
- Company
- Moderna's Spikevax bivalent Original/Omicron BA.1
- by Oct 5, 2022 06:11am
- Moderna announced on the 4th that it conducted Spikevax bivalent Original/Omicron BA.1 launch Webinar, a divalent vaccine containing omicron, on September 29. At the event, Jin Beom-sik, head of the Infectious Medicine Center at the National Medical Center, was the chairperson, and Kim Hee-soo, vice president of Moderna Korea's medical depart
- Company
- Il-Yang “has not exaggerated COVID-19 trial results
- by Kim, Jin-Gu Oct 4, 2022 06:07am
- On the 29th, Il-Yang Pharmaceutical announced that it “has not exaggerated clinical trial results” regarding the ongoing police investigation on the company’s COVID-19 drug candidate ‘Supect.’ This announcement was made in response to one media report that Il-Yang Pharmaceutical is being investigated for exaggerating the clinical tri
- Company
- Pharmaceuticals trying to dominate Saxenda obesity market
- by Moon, sung-ho Oct 4, 2022 06:07am
- The pharmaceutical and bio industries' offensive toward the obesity treatment market is getting stronger day by day. It is making all-out efforts to judge obesity as a second "endocrine" market such as diabetes. Domestic pharmaceutical companies are also continuing to move beyond Saxenda and Qsymia, which are active in the domestic obesity tr
- Company
- Industry requests re-revision of the PE exemption standards
- by Eo, Yun-Ho Sep 30, 2022 05:54am
- The pharmaceutical industry raised opposition to the government’s proposed amendment to the insurance reimbursement system. According to industry sources, the Korea-Research Based Pharmaceutical Industry Association (KRPIA) submitted an opinion statement to the government regarding the pre-announced ‘Proposal for Partial Amendment to
- Company
- development of Korea-Japan, the efficacy of COVID-19 drugs
- by Kim, Jin-Gu Sep 30, 2022 05:53am
- The difference in clinical design from Lagevrio and Paxlovid and the stop of the spread of COVID-19 are also variables. The results of phase 3 clinical trials of Xocova, a candidate for oral COVID-19 treatment under joint development by Ildong Pharmaceutical with Shionogi, Japan, have been announced. In the pharmaceutical industry, it is int
